We commenced and finished patient enrollment inside our pivotal Phase III clinical study for RI-002 in patients who suffer from Primary Immune Deficiency Illnesses . We also completed our Initial Public Giving in October 2013, raising gross proceeds of over $29 million, extending our money runway into 2016. Anticipated milestones for 2014 consist of announcing preliminary Phase III data for RI-002, seeking to list our common stock on the NASDAQ marketplace and continuing the growth and ongoing growth of our ADMA BioCenters' facilities which have continued to create year-over-year revenue boosts, stated Adam Grossman, ADMA Biologics President and CEO.Delegate research tasks: Glasgow describes dividing experts into working groups, each with single jobs including finalizing the intervention, developing the web-based tool, finalizing outcome steps, and assessing differences in contexts between analysis settings. And we gave each group decision-producing authority, Glasgow says. This allowed everybody to get the same assessment – answer the same queries and provide the same feedback. But timing and what sort of research fit into the primary care workflow was adapted to different clinics. What they got was standardized, but how they received it was localized, Glasgow says. For instance, some patients completed the assessment at home before visiting the working office, others answered queries in the waiting room, and others had staff members read the questions aloud.